PIPELINE

We have a broad portfolio of programs

in clinical and research stages

Overview

Compound
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
Approved
L/O Partners

Lazertinib
Mono-therapy

EGFR Inhibitor

NSCLC – 2nd Line Therapy

NSCLC – 1nd Line Therapy

Korea MFDS Approval
(Jan 2021)
(Jun 2023)

Lazertinib
Combo-therapy

EGFR Inhibitor  +
EGFR–MET Bispecific Antibody

NSCLC – 1st Line Therapy

USA FDA Approval
(Aug 2024) EU EC Approval
(DEC 2024)

Cevidoplenib

SYK Inhibitor

ITP

ROCK2 inhibitor

IPF

CCM

MGD Program

Mono

* NSCLC: Non-Small Cell Lung Cancer, ITP: Immune Thrombocytopenia, IPF: Idiopathic Pulmonary Fibrosis, ROCK: Rho Associated Coiled-coil Containing Protein Kinase, CCM: Cerebral Cavernous Malformations, MGD: Molecular Glue Degrader